[About degradation products of the inter-alpha-trypsin inhibitor in serum. II. Acid label derivatives of the inter-alpha-trypsin inhibitor (author's transl)].
Simultaneous to the liberation of the acid stable trypsin-plasmin-inhibitor from the inter-alpha-trypsininhibitor in vivo, acid labile degradation products are set free. The main product can be estimated by immunological methods. This product is not excreted by the kidney in contrast to the acid stable inhibitor. The product accumulates in serum in different diseases. An increased concentration of this product indicates also an increased turn-over of the inter-alpha-trypsin inhibitor in the case when the concentraton of the intact inter-alpha-trypsin inhibitor or of the filtrable derivative are within normal range.
D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional / Q000379:methods; D007249:Inflammation / Q000097:blood; D007674:Kidney Diseases / Q000097:blood; D008107:Liver Diseases / Q000097:blood; D014361:Trypsin Inhibitors / Q000097:blood*; D014511:Uremia / Q000097:blood
D014361:Trypsin Inhibitors
Uber Abbauprodukte des Inter-alpha-Trypsininhibitors im Serum. II. Säurelabile Derivate des Inter-alpha-Trypsininhibitors